Solution structures of stromelysin complexed to thiadiazole inhibitors

Protein Science

Volumn 7, Issue 11, 1998, Pages 2281-2286

  Stockman, Brian J ^a   Waldon, Daniel J ^a   Gates, Jo A ^a,c   Scahill, Terrence A ^a   Kloosterman, David A ^a   Mizsak, Stephen A ^a   Jacobsen, E Jon ^a   Belonga, Kenneth L ^a   Mitchell, Mark A ^a   Mao, Boryeu ^b   Petke, James D ^b   Goodman, Linda ^a   Powers, Elaine A ^a   Ledbetter, Steven R ^a,d   Kaytes, Paul S ^a   Vogeli, Gabriel ^a   Marshall, Vincent P ^a   Petzold, Gary L ^a   Poorman, Roger A ^a  

^a PFIZER INC   (United States)

^b Pharmacia and Upjohn ^*  (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^d Genzyme Tissue Repair   (United States)

Author keywords

Collagenase; Drug design; Matrix metalloproteinase; NMR spectroscopy; Stromelysin; Thiadiazole

Indexed keywords

COLLAGENASE; GELATINASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N METHYL 3 PHENYL 2 [3 (2 THIOXO 1,3,4 THIADIAZOL 5 YL)UREIDO]PROPIONAMIDE; PNU 142372; STROMELYSIN; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTHRITIS; ARTICLE; CANCER INHIBITION; DRUG DESIGN; DRUG MECHANISM; ENZYME ACTIVE SITE; PRIORITY JOURNAL; TISSUE REPAIR; WOUND HEALING;

EID: 0031734654     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560071105     Document Type: Article

References (22)

1. Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PMD, Cameron PM, Esser CK, Hagmann WK, Hermes JD, Springer JP. 1995. Stromelysin-1: Three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protien Sci 4:1966-1976.
2. Borkakoti N, Winkler FK, Williams DH, D'Arcy A, Broadhurst MJ, Brown, PA, Johnson WH, Murray EJ. 1994. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat Struct Biol 1:106-110.
3. Bovy PR, Getman DP, Matsoukas JM, Moore GJ. 1991. Influence of polyfluorination of the phenylalanine ring of angiotensin II on conformation and biological activity. Bioch Bioph Acta 1079:23-28.
4. Cawston TE. 1996. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 70:163-182.
5. Dhanaraj V, Ye QZ, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB Jr, Rubin JR, Pavlovsky A, Humblet C, Blundell TL. 1996. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure 4:375-386.
6. Finzel BC, Baldwin ET, Bryant GL Jr, Hess GF, Trepod CM, Mott JE, Marshall VP, Petzold GL, Poorman RA, O'Sullivan TJ, Schostarez HJ, Mitchell MA. 1998. Structural characterization of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity. Protein Sci 7:2118-2126.
7. Gooley PR, Johnson BA, Marcy AI, Cuca GC, Salowe SP, Hagmann WK, Esser CK, Springer JP. 1993. Secondary structure and zinc ligation of human recombinant short-form stromelysin by multidimensional heteronuclear NMR. Biochemistry 32:13098-13108.
8. Gooley PR, O'Connell JF, Marcy AI, Cuca GC, Axel MG, Caldwell CG, Hagmann WK, Becker JW. 1996. Comparison of the structure of human recombinant short form stromelysin by multidimensional heteronuclear NMR and X-ray crystallography. J Biomol NMR 7:8-28.
9. Gooley PR, O'Connell JF, Marcy AI, Cuca GC, Salowe SP, Bush BL, Hermes JD, Esser CK, Hagmann WK, Springer JP, Johnson BA. 1994. The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat Struct Biol 1:111-118.
10. Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W. 1995. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry 34:14012-14020.
11. Lovejoy B, Cleasby A, Hassell AM, Longley K, Luther MA, Weigl D, McGeehan G, McElroy AB, Drewry D, Lambert MH, Jordan SR. 1994. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 263:375-377.
12. MacDougall JR, Matrisian LM. 1995. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 14:351-362.
13. McCoy MA, Dellwo MJ, Schneider DM, Banks TM, Falvo J, Vavra KJ, Mathiowetz AM, Qoronfleh MW, Ciccarelli R, Cook ER, Pulvino TA, Wahl RC, Wang H. 1997. Assignments and structure determination of the catalytic domain of human fibroblast collagenase using 3D double and triple resonance NMR spectroscopy. J Biomol NMR 9:11-24.
14. Moy FJ, Pisano MR, Chanda PK, Urbano C, Killar LM, Sung M-L, Powers R. 1997. Assignments, secondary structure and dynamics of the inhibitor-free catalytic fragment of human fibroblast collagenase. J Biomol NMR 10:9-19.
15. Reinemer P, Grams F, Huber R, Kleine T, Schnierer S, Piper M, Tschesche H, Bode W. 1994. Structural implications for the role of the N terminus in the 'superactivation' of collagenases. FEBS Lett 338:227-233.
16. Spurlino JC, Smallwood AM, Carlton DD, Banks TM, Vavra KJ, Johnson JS, Cook ER, Falvo J, Wahl RC, Pulvino TA, Wendoloski JJ, Smith DL. 1994. 1.56 Å structure of mature truncated human fibroblast collagenase. Proteins Struct Funct Genet 19:98-109.
17. Stams T, Spurlino JC, Smith DL, Wahl RC, Ho TF, Qoronfleh MW, Banks TM, Rubin B. 1994. Structure of human neutrophil collagenase reveals large S1′ specificity pocket. Nat Struct Biol 1:119-123.
18. 15N NMR spectroscopy: Implications for redox potential modulation. Biochemistry 33:15298-15308.
19. Van Doren SR, Kurochkin AV, Hu W, Ye QZ, Johnson LL, Hupe DJ, Zuiderweg ERP. 1995. Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor. Protein Sci 4:2487-2498.
20. Van Doren SR, Kurochkin AV, Ye QZ, Johnson LL, Hupe DJ, Zuiderweg ERP. 1993. Assignments for the main-chain nuclear magnetic resonances and delineation of the secondary structure of the catalytic domain of human stromelysin-1 as obtained from triple-resonance 3D NMR experiments. Biochemistry 32:13109-13122.
21. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. 1997. Matrix metalloproteinase inhibitors. Invest New Drugs 15:61-75.
22. Zask A, Levin JI, Killar LM, Skotnicki JS. 1996. Inhibition of matrix metalloproteinases: Structure based design. Curr Pharm Design 2:624-661.